ReCode Therapeutics Secures Additional Funding from Cystic Fibrosis Foundation to Advance Gene Therapy
ReCode Therapeutics, a clinical-stage genetic medicines company advancing mRNA and gene correction therapies, announced new funding from the Cystic Fibrosis Foundation to support its gene correction program. Developed in collaboration with Intellia Therapeutics and its CRISPR-based DNA-writing technology, the program aims to create treatments for cystic fibrosis patients, including those unresponsive or intolerant to existing CFTR modulators.
ReCode Therapeutics Secures Additional Funding from Cystic Fibrosis Foundation to Advance Gene Therapy